{
  "id": 20618177,
  "title": "Prenetics Q3 2026 slides: revenue beats, but growth spend sinks stock",
  "url": "https://urgent.news/2026/11/18/prenetics-q3-2026-slides-revenue-beats-but-growth-spend-sinks-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T16:11:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/prenetics-q3-2026-slides-revenue-beats-but-growth-spend-sinks-stock-93CH-5036632"
  },
  "original_language": "en",
  "account": "Prenetics Global Limited announced its Q3 2026 results on November 18, 2026, with revenue exceeding expectations but causing a significant 37-42.5% drop in stock price. Shareholders reacted negatively to the company's decision to increase growth spending, which led to a much wider loss outlook for the second half of 2026. Despite the revenue growth, the adjusted EBITDA losses for the second half of 2026 are now projected to be between $30 and $35 million, a stark contrast to the previous range of $8 and $12 million. The company's IM8 wellness brand generated $62.9 million in revenue for Q3 2026, representing a 39.8% increase sequentially and a 3.7x increase year-over-year. This brand accounts for the majority of the company's revenue. While the company reported positive adjusted free cash flow of $4.1 million in Q3, this figure includes $31.6 million of net funding from General Catalyst's Customer Value Fund facility. The company's gross margin remained at 64%, and contribution profit reached $30.6 million, reflecting a 48% margin. Management's growth investment strategy is backed by validated unit economics, with General Catalyst's cohort test showing $1.68 returned per dollar of acquisition marketing. The company's earliest customer cohorts have demonstrated substantial long-term value, with the Q1 2025 cohort returning 4.06x gross profit per acquisition dollar in less than two years. Despite the rapid growth, IM8 holds just 0.14% share of the global dietary supplements category.",
  "summary": null,
  "key_points": [
    "Revenue exceeded expectations in Q3 2026",
    "Growth spending increased, causing stock price drop",
    "IM8 wellness brand drove most of the revenue growth"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}